Intercept's OCA fails a PhIII NASH trial, raising fresh doubts about its yearslong quest for an OK
Intercept Pharmaceuticals has run into another big setback in its yearslong quest to win an approval for OCA in NASH. The biotech put out word Friday morning that its Phase III REVERSE study failed the primary endpoint for the liver disease, sending its share price into a tailspin.
There was no significant improvement in fibrosis among the patients suffering from cirrhosis who were treated with obeticholic acid, with investigators hunting for a minimum 1-stage histological improvement in the disease after 18 months of therapy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.